Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11622995 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL8733711 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1456466 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL8734938 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1457152 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL5375201 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL8735257 | 1.00 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL2555276 | 0.98 | LCK (0.50) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL9861922 | 0.98 | LCK (0.50) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL181506 | 0.98 | LCK (0.50) | LCKPPARDZDHHC20ZDHHC2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871179-B2 | Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130052129-A1 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | THE GENERAL HOSPITAL CORPORATION (US) | 2013-02-28 | — | — | US | disclosed |
| US-8309053-B2 | Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid | THE GENERAL HOSPITAL CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-8268291-B2 | Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid | THE GENERAL HOSPITAL CORPORATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-7790142-B2 | Using a radiolabeled fatty acid analog such as endo-[18F] fluoro- or [123I]iodo-3,4-cyclopropylheptadecanoic acid localized in tissue of interest, imaging, determining blood flow rate | THE GENERAL HOSPITAL CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090156848-A1 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | THE GENERAL HOSPITAL CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
| US-7494642-B2 | Fatty acid derivatives; tissue-targeted therapy; tomography; cardiovascular disorders; liver disorders; kits | THE GENERAL HOSPITAL CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080214853-A1 | Labeled cycloalkylidene-containing fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart or tumor | THE GENERAL HOSPITAL CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214851-A1 | Synthesis of labeled fatty acid analogs for use in tomography | THE GENERAL HOSPITAL CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080213173-A1 | Labeled fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart, liver, or tumor; endo-vinylic variants of cycloalkyl-substituted heptadecanoic acid for example | THE GENERAL HOSPITAL CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080213178-A1 | Using a radiolabeled fatty acid analog such as endo-[18F] fluoro- or [123I]iodo-3,4-cyclopropylheptadecanoic acid localized in tissue of interest, imaging, determining blood flow rate | THE GENERAL HOSPITAL CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080206135-A1 | Using a radiolabeled fatty acid analog such as endo-[18F] fluoro- or [123I]iodo-3,4-cyclopropylheptadecanoic acid localized in tissue of interest, imaging, determining blood flow rate | THE GENERAL HOSPITAL CORPORATION (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1622602-B1 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | GEN HOSPITAL CORP (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080095702-A1 | Labeled fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart, liver, or tumor | THE GENERAL HOSPITAL CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| EP-1622602-A4 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | GEN HOSPITAL CORP (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1622602-A2 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | THE GENERAL HOSPITAL CORPORATION (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040253177-A1 | Fatty acid derivatives; tissue-targeted therapy; tomography; cardiovascular disorders; liver disorders; kits | GENERAL HOSPITAL CORPORATION, THE | 2004-12-16 | — | — | US | disclosed |
| WO-2004093650-A2 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | THE GENERAL HOSPITAL CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052129-A1 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | FABP3, FABP1, SLC27A2 | LCK 2711/4885PPARD 337/4885ZDHHC20 383/4885 |
| US-20080214851-A1 | Synthesis of labeled fatty acid analogs for use in tomography | FFAR4, FFAR3, FFAR2 | LCK 3864/4885PPARD 139/4885ZDHHC20 244/4885 |
| US-20080214853-A1 | Labeled cycloalkylidene-containing fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart or tumor | FABP3, FFAR2, FFAR1 | LCK 2883/4885PPARD 209/4885ZDHHC20 181/4885 |
| US-20080206135-A1 | Using a radiolabeled fatty acid analog such as endo-[18F] fluoro- or [123I]iodo-3,4-cyclopropylheptadecanoic acid localized in tissue of interest, imaging, determining blood flow rate | FFAR3, FFAR2, FFAR1 | LCK 2549/4885PPARD 409/4885ZDHHC20 53/4885 |
| US-20080213173-A1 | Labeled fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart, liver, or tumor; endo-vinylic variants of cycloalkyl-substituted heptadecanoic acid for example | FABP3, FABP1, FFAR2 | LCK 2135/4885PPARD 108/4885ZDHHC20 166/4885 |
| US-20080095702-A1 | Labeled fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart, liver, or tumor | FABP3, FABP1, FFAR2 | LCK 2732/4885PPARD 207/4885ZDHHC20 180/4885 |
| US-20080213178-A1 | Using a radiolabeled fatty acid analog such as endo-[18F] fluoro- or [123I]iodo-3,4-cyclopropylheptadecanoic acid localized in tissue of interest, imaging, determining blood flow rate | FFAR3, FFAR2, FFAR1 | LCK 2549/4885PPARD 409/4885ZDHHC20 53/4885 |
| US-20040253177-A1 | Fatty acid derivatives; tissue-targeted therapy; tomography; cardiovascular disorders; liver disorders; kits | FABP1, FABP3, FFAR2 | LCK 3847/4885PPARD 81/4885ZDHHC20 223/4885 |
| US-20090156848-A1 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | FABP3, FABP1, SLC27A2 | LCK 2711/4885PPARD 337/4885ZDHHC20 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.